8,600 Shares in LivaNova PLC (NASDAQ:LIVN) Purchased by Axa S.A.

Posted by on Mar 2nd, 2023

Axa S.A. acquired a new position in LivaNova PLC (NASDAQ:LIVN – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 8,600 shares of the company’s stock, valued at approximately $437,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of Montreal Can increased its holdings in shares of LivaNova by 213.3% in the 1st quarter. Bank of Montreal Can now owns 35,725 shares of the company’s stock valued at $2,912,000 after acquiring an additional 24,324 shares during the last quarter. Panagora Asset Management Inc. purchased a new position in LivaNova during the first quarter worth $256,000. Rhumbline Advisers lifted its holdings in LivaNova by 2.1% in the 1st quarter. Rhumbline Advisers now owns 147,621 shares of the company’s stock valued at $12,080,000 after purchasing an additional 2,980 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of LivaNova by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,506 shares of the company’s stock valued at $1,596,000 after buying an additional 1,859 shares during the period. Finally, Yousif Capital Management LLC lifted its stake in shares of LivaNova by 2.4% during the 1st quarter. Yousif Capital Management LLC now owns 28,279 shares of the company’s stock worth $2,314,000 after purchasing an additional 661 shares during the period. 98.89% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Trading Down 1.9 %

Shares of NASDAQ LIVN opened at $46.43 on Thursday. The company has a market cap of $2.48 billion, a PE ratio of -28.66 and a beta of 0.82. The company has a current ratio of 2.98, a quick ratio of 2.54 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average of $54.85 and a two-hundred day moving average of $53.70. LivaNova PLC has a 1-year low of $41.82 and a 1-year high of $88.00.

LivaNova (NASDAQ:LIVN – Get Rating) last announced its quarterly earnings data on Wednesday, February 22nd. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.09. The firm had revenue of $274.90 million during the quarter, compared to analyst estimates of $262.16 million. LivaNova had a positive return on equity of 10.49% and a negative net margin of 8.44%. The company’s revenue was up 1.8% on a year-over-year basis. During the same period last year, the company earned $0.57 earnings per share. As a group, equities analysts expect that LivaNova PLC will post 2.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LivaNova news, CEO Damien Mcdonald sold 2,220 shares of LivaNova stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $54.56, for a total transaction of $121,123.20. Following the completion of the sale, the chief executive officer now owns 83,749 shares of the company’s stock, valued at approximately $4,569,345.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.38% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LIVN has been the topic of a number of research reports. StockNews.com upgraded LivaNova from a “hold” rating to a “buy” rating in a report on Monday, December 19th. Piper Sandler dropped their target price on shares of LivaNova from $94.00 to $84.00 in a report on Wednesday, November 2nd. The Goldman Sachs Group decreased their price target on LivaNova from $73.00 to $63.00 and set a “buy” rating for the company in a research report on Wednesday, November 23rd. Needham & Company LLC dropped their target price on LivaNova from $88.00 to $77.00 and set a “buy” rating on the stock in a report on Wednesday, November 2nd. Finally, Barclays began coverage on LivaNova in a research report on Wednesday, December 21st. They set an “equal weight” rating and a $62.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $76.20.

About LivaNova

(Get Rating)

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products.

Featured Stories

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.